Patents by Inventor Richard O. Hynes

Richard O. Hynes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230348605
    Abstract: Methods for developing disease-related nanobodies and related products and kits are provided. The disease-specific proteins are extracellular matrix (ECM) proteins, domains or epitopes that are associated with various aspects of disease and are not present, or are present in very low quantities, in non-diseased individuals. Highly effective nanobodies capable of specifically binding to these ECM protein epitopes useful in in vivo imaging assays, the detection, diagnosis and treatment of diseases as well as monitoring therapeutic progress in a patient with a disease are provided herein.
    Type: Application
    Filed: February 28, 2023
    Publication date: November 2, 2023
    Applicants: Massachusetts Institute of Technology, Children's Medical Center Corporation, Whitehead Institute for Biomedical Research
    Inventors: Richard O. Hynes, Noor Jailkhani, Hidde L. Ploegh, Yushu J. Xie
  • Publication number: 20230295284
    Abstract: Provided herein are anti-FN-EIIIB nanobodies, conjugates thereof, and methods of using the nanobodies and conjugates thereof.
    Type: Application
    Filed: January 31, 2023
    Publication date: September 21, 2023
    Applicant: Massachusetts Institute of Technology
    Inventors: Richard O. Hynes, Karl Dane Wittrup, Noor Jailkhani, Noor Momin, Emi Lutz
  • Patent number: 11597769
    Abstract: Methods for developing disease-related nanobodies and related products and kits are provided. The disease-specific proteins are extracellular matrix (ECM) proteins, domains or epitopes that are associated with various aspects of disease and are not present, or are present in very low quantities, in non-diseased individuals. Highly effective nanobodies capable of specifically binding to these ECM protein epitopes useful in in vivo imaging assays, the detection, diagnosis and treatment of diseases as well as monitoring therapeutic progress in a patient with a disease are provided herein.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: March 7, 2023
    Assignees: Massachusetts Institute of Technology, Children's Medical Center Corporation, Whitehead Institute for Biomedical Research
    Inventors: Richard O. Hynes, Noor Jailkhani, Hidde L. Ploegh, Yushu Joy Xie
  • Publication number: 20190225693
    Abstract: Methods for developing disease-related nanobodies and related products and kits are provided. The disease-specific proteins are extracellular matrix (ECM) proteins, domains or epitopes that are associated with various aspects of disease and are not present, or are present in very low quantities, in non-diseased individuals. Highly effective nanobodies capable of specifically binding to these ECM protein epitopes useful in in vivo imaging assays, the detection, diagnosis and treatment of diseases as well as monitoring therapeutic progress in a patient with a disease are provided herein.
    Type: Application
    Filed: January 25, 2019
    Publication date: July 25, 2019
    Applicant: Massachusetts Institute of Technology
    Inventors: Richard O. Hynes, Noor Jailkhani
  • Patent number: 10024860
    Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyzes of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: July 17, 2018
    Assignees: Massachusetts Institute of Technology, The General Hospital Corporation, The Broad Institute, Inc.
    Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
  • Publication number: 20170343553
    Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.
    Type: Application
    Filed: September 22, 2016
    Publication date: November 30, 2017
    Applicants: Massachusetts Institute of Technology, The General Hospital Corporation d/b/a Massachusettes General Hospital, The Broad Institute, Inc.
    Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
  • Publication number: 20170051073
    Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.
    Type: Application
    Filed: September 22, 2016
    Publication date: February 23, 2017
    Applicants: Massachusetts Institute of Technology, The General Hospital Corporation d/b/a Massachusettes General Hospital, The Broad Institute, Inc.
    Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
  • Patent number: 9526800
    Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyzes of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: December 27, 2016
    Assignees: Massachusetts Institute of Technology, The General Hospital Corporation, The Broad Institute, Inc.
    Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
  • Publication number: 20150086565
    Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 26, 2015
    Applicants: Massachusetts Institute of Technology, The General Hospital Corporaiton d/b/a Massachusetts General Hospital, The Broad Institute, Inc.
    Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
  • Patent number: 4487838
    Abstract: A crosslinking reagent consisting of a first functional group capable of forming a covalent derivative with a material of interest; a second functional group capable of forming an in situ bond to a neighboring material upon activation; a cleavable bond separating said first and second groups; and a radioactive marker to identify the neighboring material after cleavage of said bond, whereby in situ protein interactions can be studied.
    Type: Grant
    Filed: January 12, 1982
    Date of Patent: December 11, 1984
    Assignee: Massachusetts Institute of Technology
    Inventors: Richard O. Hynes, Martin A. Schwartz